|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
molybdate inhibits the reaction [Potassium Chloride inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]] |
CTD |
PMID:3015922 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Ca4 |
carbonic anhydrase 4 |
decreases activity |
ISO |
molybdate results in decreased activity of CA4 protein |
CTD |
PMID:15664814 |
|
NCBI chr10:72,272,286...72,281,069
Ensembl chr10:72,272,248...72,281,067
|
|
G |
Ca5a |
carbonic anhydrase 5A |
decreases activity |
ISO |
molybdate results in decreased activity of CA5A protein |
CTD |
PMID:15664814 |
|
NCBI chr19:54,731,829...54,761,697
Ensembl chr19:54,731,859...54,761,670
|
|
G |
Ca9 |
carbonic anhydrase 9 |
decreases activity |
ISO |
molybdate results in decreased activity of CA9 protein |
CTD |
PMID:15664814 |
|
NCBI chr 5:59,008,277...59,015,535
Ensembl chr 5:59,008,933...59,015,528
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases activity |
ISO |
molybdate results in decreased activity of CA2 protein |
CTD |
PMID:15664814 |
|
NCBI chr 2:88,097,740...88,112,868
Ensembl chr 2:88,097,720...88,113,029
|
|
G |
Insr |
insulin receptor |
multiple interactions |
EXP |
[molybdate co-treated with INS1 protein] results in increased phosphorylation of INSR protein; [molybdate co-treated with Vanadates co-treated with INS1 protein] results in increased phosphorylation of INSR protein |
CTD |
PMID:1321133 |
|
NCBI chr12:1,682,527...1,816,414
Ensembl chr12:1,680,957...1,816,414
|
|
G |
Irs4 |
insulin receptor substrate 4 |
multiple interactions |
EXP |
[molybdate co-treated with INS1 protein] results in increased phosphorylation of IRS4 protein; molybdate promotes the reaction [[Vanadates co-treated with INS1 protein] results in increased phosphorylation of IRS4 protein]; Vanadates promotes the reaction [[molybdate co-treated with INS1 protein] results in increased phosphorylation of IRS4 protein] |
CTD |
PMID:1321133 |
|
NCBI chr X:113,003,824...113,018,088
|
|
G |
Ivl |
involucrin |
decreases expression |
ISO |
molybdate results in decreased expression of IVL protein |
CTD |
PMID:7848924 |
|
NCBI chr 2:192,761,171...192,773,346
Ensembl chr 2:192,761,538...192,763,577
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
increases expression |
EXP |
molybdate results in increased expression of NR3C1 protein |
CTD |
PMID:3015922 |
|
NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
|
|
G |
Papss1 |
3'-phosphoadenosine 5'-phosphosulfate synthase 1 |
multiple interactions |
ISO |
PAPSS1 protein binds to and affects the metabolism of molybdate |
CTD |
PMID:15065880 |
|
NCBI chr 2:236,605,695...236,680,772
Ensembl chr 2:236,605,695...236,680,772
|
|
|
G |
Cd80 |
Cd80 molecule |
increases secretion |
ISO |
molybdenum chloride results in increased secretion of CD80 protein |
CTD |
PMID:19844976 |
|
NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353
|
|
G |
Il1b |
interleukin 1 beta |
increases secretion |
ISO |
molybdenum chloride results in increased secretion of IL1B protein |
CTD |
PMID:19844976 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
increases secretion |
ISO |
molybdenum chloride results in increased secretion of IL6 protein |
CTD |
PMID:19844976 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Tnf |
tumor necrosis factor |
increases secretion |
ISO |
molybdenum chloride results in increased secretion of TNF protein |
CTD |
PMID:19844976 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Cat |
catalase |
decreases activity multiple interactions |
ISO |
molybdenum trioxide results in decreased activity of CAT protein chromous chloride affects the reaction [molybdenum trioxide results in decreased activity of CAT protein]; molybdenum trioxide affects the reaction [chromous chloride results in decreased activity of CAT protein] |
CTD |
PMID:30389395 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases activity increases expression |
ISO |
molybdenum trioxide results in increased activity of NQO1 protein molybdenum trioxide results in increased expression of NQO1 mRNA |
CTD |
PMID:9029048 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases activity |
ISO EXP |
sodium molybdate(VI) promotes the reaction [Tetrachlorodibenzodioxin binds to AHR protein] sodium molybdate(VI) inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein] sodium molybdate(VI) results in increased activity of AHR protein |
CTD |
PMID:3040233 PMID:8079350 PMID:8395819 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases phosphorylation |
ISO |
tetrathiomolybdate results in increased phosphorylation of ACACA protein |
CTD |
PMID:24218578 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
decreases expression |
ISO |
tetrathiomolybdate analog results in decreased expression of AGTR2 mRNA |
CTD |
PMID:19323979 |
|
NCBI chr X:119,389,480...119,393,845
Ensembl chr X:119,390,013...119,393,842
|
|
G |
Angpt2 |
angiopoietin 2 |
increases expression |
ISO |
tetrathiomolybdate analog results in increased expression of ANGPT2 mRNA |
CTD |
PMID:19323979 |
|
NCBI chr16:75,966,480...76,016,147
Ensembl chr16:75,966,352...76,016,195
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions affects binding |
ISO |
[tetrathiomolybdate binds to APP 5' UTR] which results in decreased expression of APP protein; [tetrathiomolybdate binds to APP 5' UTR] which results in decreased secretion of APP protein modified form |
CTD |
PMID:15681799 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Aqp1 |
aquaporin 1 |
decreases expression |
ISO |
tetrathiomolybdate analog results in decreased expression of AQP1 mRNA |
CTD |
PMID:19323979 |
|
NCBI chr 4:85,551,503...85,563,683
Ensembl chr 4:85,551,502...85,569,360
|
|
G |
Atp7a |
ATPase copper transporting alpha |
multiple interactions |
ISO |
tetrathiomolybdate inhibits the reaction [Oxygen deficiency affects the localization of ATP7A protein] |
CTD |
PMID:19351718 |
|
NCBI chr X:77,076,085...77,193,644
Ensembl chr X:77,076,106...77,193,644
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions |
ISO |
tetrathiomolybdate inhibits the reaction [ATP7B gene mutant form results in increased abundance of Copper] |
CTD |
PMID:11803042 |
|
NCBI chr16:74,865,516...74,944,935
Ensembl chr16:74,865,516...74,945,286
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
ISO |
tetrathiomolybdate analog results in increased expression of BCL2 mRNA; tetrathiomolybdate analog results in increased expression of BCL2 protein |
CTD |
PMID:19323979 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l11 |
BCL2 like 11 |
multiple interactions |
EXP |
[Copper deficiency co-treated with tetrathiomolybdate] results in increased cleavage of BCL2L11 protein; [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of BCL2L11 protein |
CTD |
PMID:22276220 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
increases expression |
ISO |
tetrathiomolybdate analog results in increased expression of BCL2L2 mRNA; tetrathiomolybdate analog results in increased expression of BCL2L2 protein |
CTD |
PMID:19323979 |
|
NCBI chr15:33,543,774...33,549,165
Ensembl chr15:33,544,312...33,549,164
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
[Copper deficiency co-treated with tetrathiomolybdate] results in increased cleavage of CASP3 protein; [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of CASP3 protein |
CTD |
PMID:22276220 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
EXP |
[Copper deficiency co-treated with tetrathiomolybdate] results in increased cleavage of CASP8 protein; [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of CASP8 protein |
CTD |
PMID:22276220 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of CCL2 mRNA]; tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of CCL2 protein]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of and results in increased expression of CCL2 protein] tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of CCL2 mRNA]; tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of CCL2 protein] |
CTD |
PMID:15541506 PMID:21724870 PMID:24225134 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
increases expression |
EXP |
tetrathiomolybdate results in increased expression of CCS protein |
CTD |
PMID:21784888 |
|
NCBI chr 1:220,075,251...220,096,319
Ensembl chr 1:220,075,247...220,096,404
|
|
G |
Cd40 |
CD40 molecule |
increases expression |
ISO |
tetrathiomolybdate analog results in increased expression of CD40 mRNA |
CTD |
PMID:19323979 |
|
NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
tetrathiomolybdate analog results in increased expression of CDKN1A protein |
CTD |
PMID:19323979 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Ckm |
creatine kinase, M-type |
multiple interactions |
ISO |
tetrathiomolybdate inhibits the reaction [Doxorubicin results in increased expression of CKM protein] |
CTD |
PMID:16242529 |
|
NCBI chr 1:80,321,507...80,331,841
Ensembl chr 1:80,321,585...80,331,841
|
|
G |
Cox5b |
cytochrome c oxidase subunit 5B |
increases expression |
ISO |
tetrathiomolybdate analog results in increased expression of COX5B mRNA |
CTD |
PMID:19323979 |
|
NCBI chr 9:43,259,706...43,262,039
Ensembl chr 9:43,259,709...43,262,040
|
|
G |
Cp |
ceruloplasmin |
decreases activity decreases expression decreases secretion multiple interactions |
ISO EXP |
tetrathiomolybdate results in decreased activity of CP protein tetrathiomolybdate results in decreased expression of CP protein tetrathiomolybdate results in decreased secretion of CP protein tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of CP protein] |
CTD |
PMID:10656425 PMID:12624602 PMID:21724870 PMID:21784888 PMID:24013775 |
|
NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
decreases expression |
EXP |
tetrathiomolybdate results in decreased expression of CPT1A mRNA |
CTD |
PMID:21784888 |
|
NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
|
|
G |
Crabp2 |
cellular retinoic acid binding protein 2 |
decreases expression |
ISO |
tetrathiomolybdate analog results in decreased expression of CRABP2 mRNA |
CTD |
PMID:19323979 |
|
NCBI chr 2:187,322,416...187,326,794
Ensembl chr 2:184,882,969...184,883,505
|
|
G |
Crebzf |
CREB/ATF bZIP transcription factor |
increases expression |
ISO |
tetrathiomolybdate analog results in increased expression of CREBZF mRNA |
CTD |
PMID:19323979 |
|
NCBI chr 1:156,290,215...156,296,891
Ensembl chr 1:156,294,519...156,296,161
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
increases expression |
ISO |
tetrathiomolybdate analog results in increased expression of CXCR4 mRNA |
CTD |
PMID:19323979 |
|
NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; tetrathiomolybdate inhibits the reaction [EGF protein results in increased oxidation of PTPN1 protein]; tetrathiomolybdate inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:18480265 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
tetrathiomolybdate inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:18480265 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Eln |
elastin |
multiple interactions |
EXP |
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of ELN mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of ELN protein |
CTD |
PMID:22276220 |
|
NCBI chr12:24,978,478...25,021,864
Ensembl chr12:24,978,483...25,021,863
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
EXP |
[Copper deficiency co-treated with tetrathiomolybdate] inhibits the reaction [EP300 protein binds to HIF1A protein]; [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of EP300 protein |
CTD |
PMID:22276220 |
|
NCBI chr 7:122,818,194...122,889,055
Ensembl chr 7:122,818,975...122,861,296
|
|
G |
Fbln1 |
fibulin 1 |
multiple interactions |
EXP |
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of FBLN1 mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of FBLN1 protein |
CTD |
PMID:22276220 |
|
NCBI chr 7:126,096,793...126,176,468
Ensembl chr 7:126,096,793...126,176,468
|
|
G |
Fbln5 |
fibulin 5 |
multiple interactions |
EXP |
[Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of FBLN5 mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of FBLN5 protein |
CTD |
PMID:22276220 |
|
NCBI chr 6:125,644,797...125,723,957
Ensembl chr 6:125,644,804...125,723,944
|
|
G |
Fbn1 |
fibrillin 1 |
multiple interactions |
EXP |
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of FBN1 mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of FBN1 protein |
CTD |
PMID:22276220 |
|
NCBI chr 3:117,569,708...117,766,160
Ensembl chr 3:117,569,697...117,766,120
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
decreases secretion |
ISO |
tetrathiomolybdate results in decreased secretion of FGF1 protein |
CTD |
PMID:18400376 |
|
NCBI chr18:32,273,830...32,359,831
Ensembl chr18:32,273,770...32,359,824
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]; Vanadates inhibits the reaction [tetrathiomolybdate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]; Vanadates inhibits the reaction [tetrathiomolybdate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:18480265 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression |
ISO |
tetrathiomolybdate analog results in increased expression of GPX3 mRNA |
CTD |
PMID:19323979 |
|
NCBI chr10:40,247,436...40,255,423
Ensembl chr10:40,247,436...40,255,422
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression |
ISO |
tetrathiomolybdate analog results in increased expression of GSR mRNA |
CTD |
PMID:19323979 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
[Copper deficiency co-treated with tetrathiomolybdate] inhibits the reaction [EP300 protein binds to HIF1A protein]; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of HIF1A protein |
CTD |
PMID:22276220 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
decreases expression |
EXP |
tetrathiomolybdate results in decreased expression of HMGCS2 mRNA |
CTD |
PMID:21784888 |
|
NCBI chr 2:200,452,623...200,480,785
Ensembl chr 2:200,452,624...200,479,423
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
decreases expression |
ISO |
tetrathiomolybdate analog results in decreased expression of RHAMM mRNA |
CTD |
PMID:19323979 |
|
NCBI chr10:25,861,490...25,890,639
Ensembl chr10:25,861,490...25,890,639
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression increases expression multiple interactions |
EXP ISO |
tetrathiomolybdate results in decreased expression of HMOX1 protein tetrathiomolybdate analog results in increased expression of HMOX1 mRNA; tetrathiomolybdate analog results in increased expression of HMOX1 protein [tetrathiomolybdate analog results in increased abundance of Superoxides] which results in increased reduction of HMOX1 protein; Acetylcysteine inhibits the reaction [tetrathiomolybdate analog results in increased expression of HMOX1 protein]; Copper inhibits the reaction [tetrathiomolybdate analog results in increased expression of HMOX1 protein] |
CTD |
PMID:19323979 PMID:21784888 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of ICAM1 mRNA]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of and results in increased expression of ICAM1 protein] tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of ICAM1 mRNA]; tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of ICAM1 protein] |
CTD |
PMID:21724870 PMID:24225134 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK3 protein]; tetrathiomolybdate inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein] |
CTD |
PMID:18480265 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions |
ISO |
tetrathiomolybdate inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein] |
CTD |
PMID:18480265 |
|
NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL1A protein] |
CTD |
PMID:21724870 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
tetrathiomolybdate inhibits the reaction [Doxorubicin results in increased expression of IL1B protein] |
CTD |
PMID:16242529 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
tetrathiomolybdate inhibits the reaction [Doxorubicin results in increased expression of IL2 protein] |
CTD |
PMID:16242529 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
decreases expression multiple interactions |
ISO |
tetrathiomolybdate analog results in decreased expression of IL2RA mRNA tetrathiomolybdate inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]] |
CTD |
PMID:19323979 PMID:23134680 |
|
NCBI chr17:70,500,672...70,547,929
Ensembl chr17:70,499,083...70,548,071
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA] |
CTD |
PMID:21724870 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Itgb4 |
integrin subunit beta 4 |
decreases expression |
ISO |
tetrathiomolybdate analog results in decreased expression of ITGB4 mRNA |
CTD |
PMID:19323979 |
|
NCBI chr10:104,524,000...104,560,180
Ensembl chr10:104,523,996...104,561,078
|
|
G |
Itgb6 |
integrin subunit beta 6 |
multiple interactions |
EXP |
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of ITGB6 mRNA |
CTD |
PMID:22276220 |
|
NCBI chr 3:46,652,624...46,775,362
Ensembl chr 3:46,652,623...46,726,958
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
increases expression |
ISO |
tetrathiomolybdate analog results in increased expression of JAG1 mRNA |
CTD |
PMID:19323979 |
|
NCBI chr 3:130,079,361...130,114,781
Ensembl chr 3:130,079,361...130,114,770
|
|
G |
Klf2 |
Kruppel-like factor 2 |
decreases expression |
ISO |
tetrathiomolybdate analog results in decreased expression of KLF2 mRNA |
CTD |
PMID:19323979 |
|
NCBI chr16:19,223,087...19,225,037
Ensembl chr16:19,223,087...19,225,037
|
|
G |
Lox |
lysyl oxidase |
multiple interactions |
EXP |
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of LOX mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of LOX protein |
CTD |
PMID:22276220 |
|
NCBI chr18:47,500,320...47,577,819
Ensembl chr18:47,500,330...47,577,819
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation |
EXP ISO |
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased phosphorylation of MAPK1 protein tetrathiomolybdate results in decreased phosphorylation of MAPK1 protein [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK1 protein]; Hydrogen Peroxide inhibits the reaction [tetrathiomolybdate results in decreased phosphorylation of MAPK1 protein]; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]; Vanadates inhibits the reaction [tetrathiomolybdate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]] tetrathiomolybdate analog results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:18480265 PMID:19323979 PMID:22276220 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation increases phosphorylation |
EXP ISO |
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased phosphorylation of MAPK3 protein tetrathiomolybdate results in decreased phosphorylation of MAPK3 protein tetrathiomolybdate analog results in increased phosphorylation of MAPK3 protein [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK3 protein]; Hydrogen Peroxide inhibits the reaction [tetrathiomolybdate results in decreased phosphorylation of MAPK3 protein]; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]; Vanadates inhibits the reaction [tetrathiomolybdate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:18480265 PMID:19323979 PMID:22276220 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
ISO |
tetrathiomolybdate inhibits the reaction [Copper results in increased phosphorylation of MAPT protein] |
CTD |
PMID:25671100 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
ISO |
tetrathiomolybdate analog affects the localization of and results in increased activity of NFE2L2 protein |
CTD |
PMID:19323979 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
tetrathiomolybdate results in decreased phosphorylation of and results in decreased degradation of NFKBIA protein |
CTD |
PMID:24225134 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression |
ISO |
tetrathiomolybdate results in decreased expression of PCNA protein |
CTD |
PMID:24614111 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
decreases expression |
ISO |
tetrathiomolybdate results in decreased expression of PDGFRB protein |
CTD |
PMID:18480265 |
|
NCBI chr18:56,364,586...56,406,381
Ensembl chr18:56,364,620...56,406,381
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression |
EXP |
tetrathiomolybdate results in decreased expression of PPARA mRNA |
CTD |
PMID:21784888 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
tetrathiomolybdate analog results in increased expression of PTGS2 mRNA |
CTD |
PMID:19323979 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
multiple interactions |
EXP |
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased phosphorylation of PTK2 protein |
CTD |
PMID:22276220 |
|
NCBI chr 7:114,436,419...114,611,317
Ensembl chr 7:114,437,361...114,590,119
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
multiple interactions |
ISO |
tetrathiomolybdate inhibits the reaction [EGF protein results in increased oxidation of PTPN1 protein] |
CTD |
PMID:18480265 |
|
NCBI chr 3:164,665,462...164,711,936
Ensembl chr 3:164,665,532...164,711,848
|
|
G |
Slc31a1 |
solute carrier family 31 member 1 |
multiple interactions increases expression |
ISO |
[tetrathiomolybdate results in increased expression of SLC31A1 mRNA] which results in decreased susceptibility to oxaliplatin; [tetrathiomolybdate results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Carboplatin; [tetrathiomolybdate results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Cisplatin; tetrathiomolybdate promotes the reaction [SP1 protein binds to SLC31A1 promoter] |
CTD |
PMID:22172574 PMID:22914438 |
|
NCBI chr 5:78,222,504...78,249,358
Ensembl chr 5:78,222,504...78,249,358
|
|
G |
Slc31a2 |
solute carrier family 31 member 2 |
decreases response to substance |
ISO |
SLC31A2 mRNA results in decreased susceptibility to tetrathiomolybdate |
CTD |
PMID:24522273 |
|
NCBI chr 5:78,120,606...78,131,111
Ensembl chr 5:78,120,607...78,131,114
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
tetrathiomolybdate analog results in increased expression of SLC7A11 mRNA |
CTD |
PMID:19323979 |
|
NCBI chr 2:139,453,774...139,528,479
Ensembl chr 2:139,453,774...139,528,162
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases expression affects localization decreases activity multiple interactions |
EXP ISO |
tetrathiomolybdate results in decreased expression of SOD1 protein tetrathiomolybdate analog affects the localization of SOD1 protein tetrathiomolybdate results in decreased activity of SOD1 protein [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK3 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] which results in decreased abundance of Hydrogen Peroxide; [tetrathiomolybdate results in decreased activity of SOD1 protein] which results in increased abundance of Superoxides; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]] tetrathiomolybdate analog results in decreased expression of SOD1 mRNA |
CTD |
PMID:18480265 PMID:19323979 PMID:21784888 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
ISO |
tetrathiomolybdate analog results in increased expression of SOD2 mRNA; tetrathiomolybdate analog results in increased expression of SOD2 protein |
CTD |
PMID:19323979 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions increases expression increases activity |
ISO |
[tetrathiomolybdate results in decreased abundance of Copper] which results in increased expression of SP1 protein; tetrathiomolybdate promotes the reaction [SP1 protein binds to SLC31A1 promoter]; tetrathiomolybdate promotes the reaction [SP1 protein binds to SP1 promoter] tetrathiomolybdate results in increased expression of SP1; tetrathiomolybdate results in increased expression of SP1 mRNA tetrathiomolybdate results in increased activity of SP1 protein |
CTD |
PMID:22172574 PMID:22914438 |
|
NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
|
|
G |
Sp3 |
Sp3 transcription factor |
decreases expression |
ISO |
tetrathiomolybdate results in decreased expression of SP3 |
CTD |
PMID:22172574 |
|
NCBI chr 3:59,644,579...59,689,011
Ensembl chr 3:59,646,015...59,688,692
|
|
G |
Tfb1m |
transcription factor B1, mitochondrial |
decreases expression |
EXP |
tetrathiomolybdate results in decreased expression of TFB1M mRNA |
CTD |
PMID:21784888 |
|
NCBI chr 1:44,433,116...44,474,674
Ensembl chr 1:44,433,116...44,474,674
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein] |
CTD |
PMID:15541506 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of TNF mRNA]; tetrathiomolybdate inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF mRNA]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein] |
CTD |
PMID:15541506 PMID:16242529 PMID:21724870 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnni3 |
troponin I3, cardiac type |
multiple interactions |
ISO |
tetrathiomolybdate inhibits the reaction [Doxorubicin results in increased expression of TNNI3 protein] |
CTD |
PMID:16242529 |
|
NCBI chr 1:72,882,806...72,886,490
Ensembl chr 1:72,882,806...72,886,488
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
[Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of TP53 protein |
CTD |
PMID:22276220 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
tetrathiomolybdate analog results in increased expression of TXNRD1 mRNA |
CTD |
PMID:19323979 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of VCAM1 mRNA]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of and results in increased expression of VCAM1 protein] tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of VCAM1 mRNA]; tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of VCAM1 protein] |
CTD |
PMID:21724870 PMID:24225134 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions decreases expression |
EXP |
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of VEGFA mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of VEGFA protein tetrathiomolybdate results in decreased expression of VEGFA protein |
CTD |
PMID:16277669 PMID:22276220 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|